Roche's Tecentriq wins FDA Priority Review in stage III colon cancer
Roche has received FDA Priority Review for a supplemental Biologics Licence Application (sBLA) covering Tecentriq (atezolizumab) in combination with FOLFOX6 chemotherapy as an adjuvant treatment for patients with stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer. The FDA is expected to issue a decision by 9 October 2026.
The application covers both the intravenous formulation, Tecentriq, and the subcutaneous version, Tecentriq Hybreza, making it the first immunotherapy-based adjuvant filing in this molecularly defined colon cancer subtype. The dMMR/MSI-H population accounts for roughly 15% of all colon cancer diagnoses, a group whose tumours carry high mutation burdens and are therefore considered more likely to respond to checkpoint inhibition.
The ATOMIC data
The filing rests on Phase III data from the ATOMIC study, a randomised, open-label trial of 712 patients sponsored by the National Cancer Institute and conducted by the Alliance for Clinical Trials in Oncology. Results were published in the New England Journal of Medicine earlier this year.
Adding Tecentriq to FOLFOX6 reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone. The 36-month disease-free survival rate was 86% in the combination arm versus 76% in the chemotherapy-only group. The safety profile was described as consistent with the established profiles of both Tecentriq and FOLFOX6 individually.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the ATOMIC results "demonstrate that Tecentriq plus chemotherapy can substantially reduce the risk of disease recurrence or death, helping more patients remain cancer-free following surgery."
Regulatory and market context
Priority Review designation shortens the standard FDA review clock from twelve months to six, reflecting the agency's view that the therapy addresses an unmet medical need. Approximately 30% of stage III colon cancer patients relapse within five years despite surgery and chemotherapy, a statistic that has driven sustained investment in adjuvant strategies across the sector.
The dMMR/MSI-H biomarker has become a central axis of precision oncology in colorectal cancer. Pembrolizumab (Merck's Keytruda) is already approved by the FDA as a first-line treatment in metastatic MSI-H colorectal cancer, and its extension into the curative-intent adjuvant setting has been widely anticipated. A positive Tecentriq decision in October would represent the first approved immunotherapy in the adjuvant colon cancer space and could intensify competition for pembrolizumab's position across the MSI-H patient continuum.
Roche has also indicated it intends to file with the European Medicines Agency, broadening the potential addressable population beyond the United States. The companion diagnostic element is notable: the sBLA specifies tumour dMMR status determined by immunohistochemistry, with the VENTANA MMR RxDx Panel named in the filing, reinforcing the diagnostics-driven market access model Roche has applied across its oncology portfolio.
Investors will watch the October PDUFA date closely. A full approval would strengthen Tecentriq's commercial position at a time when the broader PD-(L)1 class faces genericisation pressure in some indications and growing biosimilar scrutiny in others.